209 related articles for article (PubMed ID: 29338092)
21. Post-surgical thyroid ablation with low or high radioiodine activities results in similar outcomes in intermediate risk differentiated thyroid cancer patients.
Castagna MG; Cevenini G; Theodoropoulou A; Maino F; Memmo S; Claudia C; Belardini V; Brianzoni E; Pacini F
Eur J Endocrinol; 2013 Jul; 169(1):23-9. PubMed ID: 23594687
[TBL] [Abstract][Full Text] [Related]
22. Response to Surgery Assessments for Sparing Radioiodine Remnant Ablation in Intermediate-Risk Papillary Thyroid Cancer.
Zhang X; Liu JR; Mu ZZ; Cheng XQ; Lin YS
J Clin Endocrinol Metab; 2023 May; 108(6):1330-1337. PubMed ID: 36567646
[TBL] [Abstract][Full Text] [Related]
23. Is radioiodine ablation with 1.1 GBq (30 mCi)
Ilera V; Califano I; Cavallo A; Faure E; Vázquez A; Pitoia F;
Endocrine; 2023 Jun; 80(3):606-611. PubMed ID: 36988853
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of radioiodine therapy for treating 20 patients with pulmonary metastases from differentiated thyroid cancer and a meta-analysis of the current literature.
Zhang X; Liu DS; Luan ZS; Zhang F; Liu XH; Zhou W; Zhong SF; Lai H
Clin Transl Oncol; 2018 Jul; 20(7):928-935. PubMed ID: 29119458
[TBL] [Abstract][Full Text] [Related]
25. Radioiodine (131I) treatment decision-making for low- and intermediate-risk differentiated thyroid cancer.
Gao H; Huang J; Dai Q; Su J
Arch Endocrinol Metab; 2023 Mar; 67(2):197-205. PubMed ID: 36651706
[TBL] [Abstract][Full Text] [Related]
26. Determining patient selection tool and response predictor for outpatient 30 mCi radioiodine ablation dose in non-metastatic differentiated thyroid carcinoma: a Japanese perspective.
Higuchi T; Achmad A; Binh DD; Bhattarai A; Tsushima Y
Endocr J; 2018 Mar; 65(3):345-357. PubMed ID: 29343651
[TBL] [Abstract][Full Text] [Related]
27. Recurrent disease in juvenile differentiated thyroid carcinoma: prognostic factors, treatments, and outcomes.
Mihailovic J; Nikoletic K; Srbovan D
J Nucl Med; 2014 May; 55(5):710-7. PubMed ID: 24722527
[TBL] [Abstract][Full Text] [Related]
28. Non-suppressed thyrotropin and elevated thyroglobulin are independent predictors of recurrence in differentiated thyroid carcinoma.
Böhm J; Kosma VM; Eskelinen M; Hollmen S; Niskanen M; Tulla H; Alhava E; Niskanen L
Eur J Endocrinol; 1999 Nov; 141(5):460-7. PubMed ID: 10576761
[TBL] [Abstract][Full Text] [Related]
29. Transient early increase in thyroglobulin levels post-radioiodine ablation in patients with differentiated thyroid cancer.
Stevic I; Dembinski TC; Pathak KA; Leslie WD
Clin Biochem; 2015 Jul; 48(10-11):658-61. PubMed ID: 25895485
[TBL] [Abstract][Full Text] [Related]
30. Negative remnant
Lan W; Gege Z; Ningning L; Qiang W; Lin B; Qingjie M; Bin J
Ann Nucl Med; 2019 Feb; 33(2):112-118. PubMed ID: 30374858
[TBL] [Abstract][Full Text] [Related]
31. Importance of postoperative stimulated thyroglobulin level at the time of 131I ablation therapy for differentiated thyroid cancer.
Hasbek Z; Turgut B; Kilicli F; Altuntas EE; Yucel B
Asian Pac J Cancer Prev; 2014; 15(6):2523-7. PubMed ID: 24761858
[TBL] [Abstract][Full Text] [Related]
32. DELAYED 131-I FIRST TREATMENT AFTER SURGERY HAS NO IMPACT ON THE MEDIAN TERM OUTCOME OF PATIENTS WITH INTERMEDIATE RISK DIFFERENTIATED THYROID CANCER.
Matrone A; Gambale C; Torregrossa L; Piaggi P; Bianchi F; Valerio L; Viola D; Agate L; Molinaro E; Materazzi G; Basolo F; Vitti P; Elisei R
Endocr Pract; 2020 Jan; 26(1):58-71. PubMed ID: 31557080
[No Abstract] [Full Text] [Related]
33. Unexplained Hyperthyroglobulinemia in Differentiated Thyroid Cancer Patients as an Indication for Radioiodine Adjuvant Therapy: A Prospective Multicenter Study.
Cheng L; Sa R; Luo Q; Fu H; Jin Y; Tang L; Yang Y; Yu C; Chen L
J Nucl Med; 2021 Jan; 62(1):62-68. PubMed ID: 32358095
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of low radioiodine activity versus intermediate-high activity in the ablation of low-risk differentiated thyroid cancer.
Albano D; Bonacina M; Durmo R; Bertagna F; Giubbini R
Endocrine; 2020 Apr; 68(1):124-131. PubMed ID: 31784881
[TBL] [Abstract][Full Text] [Related]
35. Fractionated dosage of radioiodine for the ablation of low-risk differentiated thyroid cancer has no impact on survival.
Woliński K; Czepczyński R; Stangierski A; Trojanowski M; Rewaj-Łosyk M; Ziemnicka K; Bączyk M; Dyzmann-Sroka A; Ruchała M
Endokrynol Pol; 2018; 69(3):230-234. PubMed ID: 29504625
[TBL] [Abstract][Full Text] [Related]
36. Low- and high-dose radioiodine therapy for low-/intermediate-risk differentiated thyroid cancer: a preliminary clinical trial.
Qu Y; Huang R; Li L
Ann Nucl Med; 2017 Jan; 31(1):71-83. PubMed ID: 27757803
[TBL] [Abstract][Full Text] [Related]
37. Low but measurable stimulated serum thyroglobulin levels <2 µg/L frequently predict incomplete response in differentiated thyroid cancer patients.
Aldawish M; Jha N; McEwan AJ; Severin D; Ghosh S; Morrish DW
Endocr Res; 2014; 39(4):157-63. PubMed ID: 24460082
[TBL] [Abstract][Full Text] [Related]
38. Second Radioiodine Treatment: Limited Benefit for Differentiated Thyroid Cancer With Locoregional Persistent Disease.
Hirsch D; Gorshtein A; Robenshtok E; Masri-Iraqi H; Akirov A; Duskin Bitan H; Shimon I; Benbassat C
J Clin Endocrinol Metab; 2018 Feb; 103(2):469-476. PubMed ID: 29126111
[TBL] [Abstract][Full Text] [Related]
39. Treatment for microcarcinoma of the thyroid--clinical experience.
Küçük NO; Tari P; Tokmak E; Aras G
Clin Nucl Med; 2007 Apr; 32(4):279-81. PubMed ID: 17413573
[TBL] [Abstract][Full Text] [Related]
40. Usefulness of second 131I treatment in biochemical persistent differentiated thyroid cancer patients.
Gambale C; Prete A; Contartese L; Torregrossa L; Bianchi F; Molinaro E; Materazzi G; Elisei R; Matrone A
Eur Thyroid J; 2023 Dec; 12(6):. PubMed ID: 37855417
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]